Drug Profile

AK 152

Alternative Names: AK-152

Latest Information Update: 12 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Akeso Biopharma
Class Antidementias; Bispecific antibodies
Mechanism of Action Amyloid beta-protein modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Alzheimer's disease

Most Recent Events

16 Nov 2025 Preclinical trials in Alzheimer's disease in China (Parenteral), prior to November 2025
16 Nov 2025 The National Medical Products Administration (NMPA) approves CTA to initiate clinical trials for AK 152 in Alzheimer's disease
16 Nov 2025 Pharmacodynamics data from preclinical trial in Alzheimer's disease released by Akeso Biopharma, prior to November 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com